Vinayak Shanbhag, MD | |
110 Irving St Nw, Washington, DC 20010-2976 | |
(301) 946-5100 | |
(301) 929-0348 |
Full Name | Vinayak Shanbhag |
---|---|
Gender | Male |
Speciality | Anesthesiology |
Experience | 37 Years |
Location | 110 Irving St Nw, Washington, District Of Columbia |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1295755973 | NPI | - | NPPES |
0093 | Other | DC | CAREFIRST BCBS |
2607784 | Other | DC | AETNA HMO |
441059 | Other | VA | ANTHEM BCBS |
7697057 | Other | DC | AETNA NON HMO |
493318 | Other | DC | NCPPO |
5705231 | Medicaid | VA | |
200137 | Other | DC | KAISER |
1186064001 | Other | DC | CIGNA HMO |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | MD30974 (District Of Columbia) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Medstar Washington Hospital Center | Washington, DC | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Medstar Medical Group Anesthesiology Llc | 1052678034 | 456 |
News Archive
Leprosy, otherwise referred to as Hansen's Disease, is one of the most ancient diseases known to humans. Although the World Health Organization declared leprosy to be under control in many previously endemic countries, most experts agree that current approaches to treating the disease are not sufficient to eliminate the disease as a public health problem. Currently, 1.6 billion people are considered at risk of exposure to leprosy, while over 800 new cases occur every day.
Researchers at Spectrum Health Helen DeVos Children's Hospital have completed the first clinical trial of a new treatment for children suffering from neuroblastoma. In a clinical trial led by Giselle Sholler, MD, pediatric oncologist at Helen DeVos Children's Hospital and the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), DFMO, an investigational agent, showed minimal side effects with long-term survival of three patients.
Spectrum Pharmaceuticals today announced that it has acquired 100% rights to RenaZorb (a family of compounds represented by SPI-014, also known as RZB-014), a lanthanum-based nanotechnology compound with potent and selective phosphate binding properties, for all human and non-human indications.
The WHO's leadership is particularly important in the fight to combat HIV/AIDS. Last week, Canada bolstered its financial commitment to this effort with contributions of $100 million for WHO's '3 by 5 initiative', and $70 million to the Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria. Canada and Canadians are proud to take these actions against HIV/AIDS.
Even early in adulthood, aging begins to slow the mind's growth - but it does not have to stop it altogether, suggests a Princeton University study on the brains of adult monkeys.
› Verified 1 days ago
Entity Name | Medstar Medical Group Anesthesiology Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1528578333 PECOS PAC ID: 1052678034 Enrollment ID: O20171129001837 |
News Archive
Leprosy, otherwise referred to as Hansen's Disease, is one of the most ancient diseases known to humans. Although the World Health Organization declared leprosy to be under control in many previously endemic countries, most experts agree that current approaches to treating the disease are not sufficient to eliminate the disease as a public health problem. Currently, 1.6 billion people are considered at risk of exposure to leprosy, while over 800 new cases occur every day.
Researchers at Spectrum Health Helen DeVos Children's Hospital have completed the first clinical trial of a new treatment for children suffering from neuroblastoma. In a clinical trial led by Giselle Sholler, MD, pediatric oncologist at Helen DeVos Children's Hospital and the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), DFMO, an investigational agent, showed minimal side effects with long-term survival of three patients.
Spectrum Pharmaceuticals today announced that it has acquired 100% rights to RenaZorb (a family of compounds represented by SPI-014, also known as RZB-014), a lanthanum-based nanotechnology compound with potent and selective phosphate binding properties, for all human and non-human indications.
The WHO's leadership is particularly important in the fight to combat HIV/AIDS. Last week, Canada bolstered its financial commitment to this effort with contributions of $100 million for WHO's '3 by 5 initiative', and $70 million to the Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria. Canada and Canadians are proud to take these actions against HIV/AIDS.
Even early in adulthood, aging begins to slow the mind's growth - but it does not have to stop it altogether, suggests a Princeton University study on the brains of adult monkeys.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Vinayak Shanbhag, MD 11510 Georgia Ave, Suite 206, Wheaton, MD 20902-1925 Ph: (301) 946-5100 | Vinayak Shanbhag, MD 110 Irving St Nw, Washington, DC 20010-2976 Ph: (301) 946-5100 |
News Archive
Leprosy, otherwise referred to as Hansen's Disease, is one of the most ancient diseases known to humans. Although the World Health Organization declared leprosy to be under control in many previously endemic countries, most experts agree that current approaches to treating the disease are not sufficient to eliminate the disease as a public health problem. Currently, 1.6 billion people are considered at risk of exposure to leprosy, while over 800 new cases occur every day.
Researchers at Spectrum Health Helen DeVos Children's Hospital have completed the first clinical trial of a new treatment for children suffering from neuroblastoma. In a clinical trial led by Giselle Sholler, MD, pediatric oncologist at Helen DeVos Children's Hospital and the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), DFMO, an investigational agent, showed minimal side effects with long-term survival of three patients.
Spectrum Pharmaceuticals today announced that it has acquired 100% rights to RenaZorb (a family of compounds represented by SPI-014, also known as RZB-014), a lanthanum-based nanotechnology compound with potent and selective phosphate binding properties, for all human and non-human indications.
The WHO's leadership is particularly important in the fight to combat HIV/AIDS. Last week, Canada bolstered its financial commitment to this effort with contributions of $100 million for WHO's '3 by 5 initiative', and $70 million to the Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria. Canada and Canadians are proud to take these actions against HIV/AIDS.
Even early in adulthood, aging begins to slow the mind's growth - but it does not have to stop it altogether, suggests a Princeton University study on the brains of adult monkeys.
› Verified 1 days ago
Dr. Fay Horng, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw, Washington, DC 20010 Phone: 202-877-7504 | |
Dr. Matthew Mueller, DO, MPH Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw, Washington, DC 20010 Phone: 202-877-7000 | |
Dr. Shane Zamani, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 900 23rd St Nw, Washington, DC 20037 Phone: 202-715-4750 | |
Dr. Thomas Edward Borsari, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 50 Irving St Nw, Dept Of Anesthesiology, Washington, DC 20422 Phone: 202-745-8000 | |
Alexis Lambros, CAA Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-476-2025 | |
Susan Verghese, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-884-2025 | |
Joan Threlfall, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Rd Nw, Washington, DC 20007 Phone: 202-444-8640 |